Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19
Clinical trial NCT04519437 · COMPLETED
Trial details
- NCT number
- NCT04519437
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-26
- Primary completion
- 2021-11-22
- Enrollment
- 974
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.